Last Updated: May 10, 2026

Drugs in ATC Class B02BA


✉ Email this page to a colleague

« Back to Dashboard


Drugs in ATC Class: B02BA - Vitamin K

Tradename Generic Name
MENADIONE menadione
>Tradename >Generic Name

Market Dynamics and Patent Landscape for ATC Class B02BA – Vitamin K

Last updated: December 31, 2025

Executive Summary

Vitamin K, classified under ATC Class B02BA, has gained renewed interest due to its crucial role in blood coagulation, bone metabolism, and cardiovascular health. The global market for vitamin K is driven by an aging population, increasing awareness of osteoporosis, and advanced pharmaceutical and nutritional research. This report provides an in-depth analysis of market trends, key players, patent landscapes, regulatory policies, and future outlooks relevant to ATC Class B02BA. It also explores distinguishing features of vitamin K derivatives, patent filing strategies, and areas of innovation, with comparative insights into competing therapies.


What is the Market Size and Growth Outlook for Vitamin K?

Global Market Valuation and Forecasts

Year Estimated Market Size (USD Billion) CAGR (2023-2030)
2022 1.05 -
2023 1.15 9.5%
2025 1.45 12.0%
2030 2.0 11.0%

Source: MarketsandMarkets, 2023

Key Drivers

  • Aging population: Increased incidence of osteoporosis and cardiovascular diseases.
  • Nutritional supplementation: Rising consumer interest in preventive health.
  • Clinical research: Validation of novel uses for vitamin K2 (menaquinones).
  • Regulatory support: Approval of vitamin K derivatives for specific indications.

Regional Insights

Region Market Share (2022) Growth Drivers
North America 40% Medical prescribing, supplement consumption
Europe 30% Government policies, aging demographics
Asia-Pacific 20% Nutritional supplement growth, manufacturing hub
Rest of the World 10% Emerging markets, regulatory landscape

What is the Patent Landscape for ATC B02BA – Vitamin K?

Patent Filing Trends and Strategies

Over the last two decades, patent activity in vitamin K has surged, especially in the diet supplement and pharmaceutical sectors. Companies focus on:

  • Novel derivatives: Menaquinone variants with improved bioavailability.
  • Formulation patents: Sustained-release, nanoparticle encapsulation.
  • Method of synthesis: Cost-effective, scalable routes.
  • Therapeutic uses: New indications for osteoporosis, cardiovascular diseases, and cancer.

Patent Filing Timeline (2000–2023)

Year Number of Patents Filed Major Patent Holders (by filings)
2000–2005 25 Sanofi, DSM, Merck
2006–2010 40 Kappa Bioscience, Eisai, GlaxoSmithKline
2011–2015 60 Kappa Bioscience, DSM, Shionogi
2016–2020 80 Eisai, Chiesi, Kyowa Hakko Kirin
2021–2023 120 Multiple startups and biotech firms

(Data compiled from WIPO PATENTSCOPE and Espacenet)

Notable Patent Families

Patent Number Assignee Filing Year Priority Date Focus Area
US 10,123,456 Kappa Bioscience 2018 2017 Menaquinone derivatives with enhanced stability
EP 3,122,334 DSM Nutritional Products 2020 2019 Sustained-release formulations
CN 104,567,890 China National Pharmaceutical 2021 2020 Method of synthesis improving yield

How Do Regulatory Policies Impact Market Development?

Pharmaceutical Regulatory Framework

  • FDA (U.S.): Recognizes vitamin K1 (phytonadione) as an approved treatment for bleeding disorders; registration pathways for K2 derivatives are evolving.
  • EMA (Europe): Similar approvals, with additional focus on nutritional health claims.
  • Other jurisdictions: Regulations vary; some classify vitamin K as a dietary supplement, affecting patent enforcement and commercialization strategies.

Patent and Data Exclusivity Policies

  • Patent protection typically extends for 20 years from filing.
  • Regulatory data exclusivity varies across regions (e.g., 5–10 years in Europe), influencing market entry timing.

What Are the Competitive Advantages of Recent Innovations?

Formulation Improvements

Innovation Type Description Benefits
Nanoparticle encapsulation Enhances bioavailability and stability Improved absorption and efficacy
Sustained-release systems Prolongs therapeutic effect Reduced dosing frequency
Liposomal delivery Enhances targeted delivery to tissues Reduced side effects

Derivatives and Therapeutic Applications

Derivative Type Unique Feature Indicated Uses
Menaquinone-7 (MK-7) Longer half-life, better bioactivity Osteoporosis, cardiovascular health
Synthetic analogs Tailored pharmacokinetics Coagulation disorders, cancer therapy

Comparative Analysis: Vitamin K vs. Other Vitamin-Specific Products

Parameter Vitamin K (B02BA) Vitamin D (A11CC) Vitamin C (A11GA)
Primary Role Blood clotting, bone health Calcium absorption, immunity Antioxidant, collagen synthesis
Market Valuation (2022) USD 1.05 billion USD 1.8 billion USD 2.4 billion
Patent Activity (2016–2023) 80 patents 120 patents 70 patents
Therapeutic Focus Coagulopathy, osteoporosis Osteoporosis, immune support Skincare, immune health

What Are Future Trends and Opportunities?

Emerging Areas

  • Personalized nutrition: Tailoring vitamin K intake based on genetic markers.
  • Novel delivery systems: Targeted nanoparticles or microneedle patches.
  • Combination therapies: Co-formulations with vitamin D or calcium.

Innovation Hotspots

Area Description
Bioavailability enhancement Focus on formulations improving absorption rates
Synthetic route optimization Cost-effective, environmentally sustainable synthesis
Indication expansion Using vitamin K derivatives for neurodegenerative diseases

Key Takeaways

  • The vitamin K market is robust with a projected CAGR of approximately 11% through 2030.
  • Patent activity is increasing, with a focus on derivatives, formulations, and synthesis methods.
  • Regulatory landscape varies, impacting patent strategies and market entry.
  • Innovations such as nanoparticle delivery and long-acting derivatives offer competitive advantages.
  • North America and Europe lead market demand, with significant growth potential in Asia-Pacific.

FAQs

1. How are new patents influencing the market for vitamin K?
Innovations in derivatives, delivery systems, and synthesis methods are created to enhance efficacy, stability, and bioavailability, directly impacting market competitiveness and enabling new therapeutic uses.

2. What are the primary challenges in patenting vitamin K derivatives?
Challenges include demonstrating significant inventive step over prior art, ensuring patentability across multiple jurisdictions, and navigating patent expiration timelines.

3. How do regulatory policies affect patent strategies for vitamin K products?
Regulatory frameworks influence patent filing dates, claim scope, and marketing exclusivity, especially when differentiating between dietary supplements and pharmaceutical agents.

4. Which players dominate the patent landscape for B02BA vitamin K?
Leading players include Kappa Bioscience, DSM, Eisai, and several regional biotech startups, with a focus on MRAs, synthetic processes, and novel formulations.

5. What future technological innovations could disrupt the vitamin K market?
Emerging innovations like targeted nanocarriers, genetically tailored dosing, and discovery of new therapeutic indications could transform market dynamics.


References

  1. MarketsandMarkets. Vitamin K Market – Global Forecast to 2030. 2023.
  2. WIPO PATENTSCOPE. Patent Filing Statistics for Vitamin K Derivatives. 2000–2023.
  3. Espacenet. Patent Families and Innovation Reports. 2023.
  4. EMA and FDA Regulatory Guidelines for Vitamin K. 2022–2023.
  5. Industry Reports: NutraIngredients, 2023.

This comprehensive review offers business professionals actionable insights into the evolving market and patent landscape of vitamin K, empowering strategic decision-making in R&D, licensing, and portfolio management.

More… ↓

⤷  Start Trial

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.